Traveler-based SARS-CoV-2 Genomic Surveillance Program

The Traveler-based Genomic Surveillance program (TGS) has two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens using molecular testing and genomic sequencing and (2) filling in gaps in global biosurveillance. CDC is looking for available vendors to establish sample collection sites in several major US international airports, including New York John F Kennedy, Newark International, San Francisco International, Dulles International Airport , Seattle-Tacoma International Airport, and Los Angeles International Airport. The contractor will also develop digital data collection instruments, enrollment materials, recruit and enroll program participants, and collect biological samples (e.g., dry nasal swabs) from travelers’ arriving in the United States at the designated airports. Demographic, travel, and clinical information from participating passengers will be collected to identify the sample, but no personally identifiable information will be collected from travelers. UPDATE 12/18/2023 NCEZID may decide to schedule oral capability briefings with any or all responders to this Sources Sought Notice to gather more information for market research.